P1123: TEMPO: A PHASE 2, RANDOMIZED, OPEN-LABEL, 2-ARM STUDY COMPARING TWO INTERMITTENT DOSING SCHEDULES OF DUVELISIB IN SUBJECTS WITH INDOLENT NON-HODGKIN LYMPHOMA (INHL) by V. Vorobyev, D. H. Yoon, M. Kaźmierczak, S. Grosicki, C. Tarella, A. Genua, J. S. Kim, D. Cohan, M. Daugherty, I. W. Flinn, P. L. Zinzani, L. I. Gordon

Get full text

P1172: DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA FROM THE PHASE 2 PRIMO TRIAL: UPDATED EXPANSION PHASE ANALYSIS by P. L. Zinzani, MD, PhD, J. Zain, MD, M. Mead, BS, MD, C. Casulo, MD, E. D. Jacobsen, MD, G. Gritti, MD, PhD, L. Pinter-Brown, MD, K. Isutzu, MD, D. Cohan, MD, M. Daugherty, PharmD, J. E. Brammer, MD, N. Mehta-Shah, MD, B. Pro, MD, S. M. Horwitz, MD

Get full text